Renaissance Technologies’s Candel Therapeutics CADL Stock Holding History

Renaissance Technologies’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,780	Closed	-$62.6K	–	3227
2026 Q1	$62.6K	Buy	+12,780	New	+$69.5K	﹤0.01%	3088
2025 Q3	–	Sell	-163,600	Closed	-$828K	–	3532
2025 Q2	$828K	Buy	+163,600	New	+$842K	﹤0.01%	2597
2024 Q3	–	Sell	-20,600	Closed	-$128K	–	3548
2024 Q2	$128K	Sell	20,600 -36,305	-64%	-$272K	﹤0.01%	3140
2024 Q1	$90K	Buy	56,905 +38,230	+205%	+$56.8K	﹤0.01%	3390
2023 Q4	$27K	Buy	+18,675	New	+$18.1K	﹤0.01%	3543
2023 Q3	–	Sell	-12,800	Closed	-$16K	–	3696
2023 Q2	$16K	Sell	12,800 -8,200	-39%	-$12.1K	﹤0.01%	3795
2023 Q1	$28K	Buy	+21,000	New	+$41K	﹤0.01%	3766

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies's CADL Position: Q2 2026 in Review

Renaissance Technologies sold out of Candel Therapeutics (CADL) in Q2 2026, closing a stake of 12,780 shares — an estimated $62.6K sold.

Renaissance Technologies first reported a position in CADL in Q1 2023 and held it in 7 quarters. The position peaked at $828K in Q2 2025. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

Renaissance Technologies reported no remaining Candel Therapeutics position as of Q2 2026 after selling out during the quarter.
Renaissance Technologies sold 12,780 Candel Therapeutics shares in Q2 2026, an estimated $62.6K.
Renaissance Technologies first reported a position in Candel Therapeutics in Q1 2023 and held it in 7 quarters.
Renaissance Technologies's Candel Therapeutics position peaked at $828K in Q2 2025.
137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.